JIN Yang Pharmaceutical진양제약
007370 · KOSDAQ · ₩007370 · 진양제약
- Market cap
- ₩49B
- Enterprise value
- ₩45B
- P/E
- 2.1×
- P/B
- 0.3×
- Dividend yield
- 4.3%
- ROE
- 14.1%
- Net margin
- 18.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−39.4% from the high
₩3,310Today: ₩3,425 – ₩3,555₩5,700
Returns
- 1W−9.0%
- 1M−13.5%
- 3M−5.1%
- 6M−30.2%
- YTD−31.3%
- 1Y−37.2%
- Volume today
- 31,183
- 0.3× the 20-day average
- Traded today
- ₩108M
- Listed shares
- 14,134,587
- EPS (12 months)
- ₩1,613
- Earnings yield 46.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-13.8% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
JIN Yang Pharmaceutical stock overview
JIN Yang Pharmaceutical (진양제약, KRX: 007370) is listed on KOSDAQ, in the Biotech & Pharma sector. The company manufactures and sells pharmaceuticals, including exporting and importing, as its main business segment. Its shares closed at ₩3,455 on Oct 29, 2026, down 2.26% on the day, giving it a market value of ₩49B.
Key facts
- Market cap
- ₩49B
- Sector
- Biotech & Pharma
- Latest price change
- −2.26%
- As of
- Oct 29, 2026
- Main business
- The company manufactures and sells pharmaceuticals, including exporting and importing, as its main business segment.
Quick answers about JIN Yang Pharmaceutical
- What does JIN Yang Pharmaceutical do?
- The company manufactures and sells pharmaceuticals, including exporting and importing, as its main business segment. Its key products fall mainly into circulatory system drugs, which it names as its core product line, followed by central nervous system drugs, digestive system drugs, and other metabolic drugs, sold primarily in the domestic market. It operates in South Korea, with a small share of sales from exports, and produces tablets, hard capsules, and dry syrups at its own plants.
- What is the market cap of JIN Yang Pharmaceutical?
- The market capitalisation of JIN Yang Pharmaceutical was ₩49B at the close on Oct 29, 2026.
- Who are the largest shareholders of JIN Yang Pharmaceutical?
- According to the latest official filings, the largest reported holders are Choi Jae-jun (26.15%, as of Jun 5, 2026); Zenith Value Asset (6.08%, as of Oct 16, 2025); Korea Securities Finance (3.95%, as of Apr 9, 2025).
- When is the next earnings report from JIN Yang Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when JIN Yang Pharmaceutical filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
The company manufactures and sells pharmaceuticals, including exporting and importing, as its main business segment. Its key products fall mainly into circulatory system drugs, which it names as its core product line, followed by central nervous system drugs, digestive system drugs, and other metabolic drugs, sold primarily in the domestic market. It operates in South Korea, with a small share of sales from exports, and produces tablets, hard capsules, and dry syrups at its own plants.
Written by AI from the company's latest annual report.
- Korean name
- 진양제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 최재준
- Founded
- Jun 1978
- Listed
- Jul 2000
- Listed shares
- 14,134,587
- Fiscal year ends
- Month 12
- Website
- www.jinyangpharm.co.kr
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Half-year report (Jun 2026)Aug 13, 2026
- 5%+ holding reportJun 5, 2026
- Insider shareholding reportJun 5, 2026
- Adjustment of Conversion PriceMay 26, 2026
- 5%+ holding reportMay 18, 2026
Titles in Korean until English translations are added.
Also known as: JIN Yang Pharmaceutical / 진양제약 / 007370 / KRX:007370
Source: KRX statistical information